Browse 100+ evidence-based profiles with community ratings, dosage guides, and safety information.
Start ExploringPublished 25 March 2026
Dementia is not a single disease but a syndrome - a cluster of symptoms including progressive memory loss, impaired reasoning, personality changes, and declining ability to perform daily activities. Alzheimer's disease accounts for approximately 60-70% of dementia cases, followed by vascular dementia (15-20%), Lewy body dementia, and frontotemporal dementia. In the UK, over 900,000 people currently live with dementia, a figure projected to exceed 1.5 million by 2040.
While no supplement can cure or reverse established dementia, a growing body of evidence supports the use of specific nootropics for two purposes: risk reduction in cognitively healthy individuals and those with mild cognitive impairment (MCI), and symptom management as an adjunct to conventional treatment. This guide reviews the strongest evidence for both applications, with particular attention to compounds that target the known pathological mechanisms of dementia. For age-related cognitive decline that has not progressed to dementia, see our Nootropics for Seniors guide.
Medical disclaimer: Dementia is a serious medical condition that requires professional diagnosis and treatment. The supplements discussed here are not replacements for medical care. Always consult a doctor or specialist before starting any supplement, particularly if taking cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or memantine. Some supplements can interact with these medications.
Alzheimer's disease involves three interconnected pathological processes. First, misfolded amyloid-beta protein accumulates as plaques between neurons, triggering inflammatory cascades and disrupting synaptic communication. Second, tau protein becomes hyperphosphorylated and forms neurofibrillary tangles inside neurons, destroying the internal transport system that keeps cells alive. Third, and most relevant to nootropic intervention, the cholinergic neurons of the basal forebrain progressively degenerate, leading to severe acetylcholine deficiency that drives the hallmark memory and attention deficits. This cholinergic loss is why all currently approved Alzheimer's drugs (donepezil, rivastigmine, galantamine) work by boosting acetylcholine levels.
Vascular dementia results from impaired blood flow to the brain, caused by stroke, small vessel disease, or chronic hypoperfusion. The cognitive profile differs from Alzheimer's - executive function (planning, organisation, decision-making) is typically affected earlier and more severely than memory. Risk factors include hypertension, diabetes, smoking, and high cholesterol. Nootropics that improve cerebral blood flow and protect vascular endothelium are particularly relevant here.
Both Alzheimer's and vascular dementia involve chronic neuroinflammation and oxidative stress as both causes and consequences of neuronal damage. Activated microglia release inflammatory cytokines that damage surrounding neurons, amyloid plaques trigger oxidative cascades, and mitochondrial dysfunction generates excess reactive oxygen species. Anti-inflammatory and antioxidant compounds can help interrupt these self-reinforcing damage cycles.
Ginkgo biloba, specifically the standardised extract EGb 761, has the largest evidence base of any supplement for dementia. It works through three mechanisms directly relevant to dementia pathology: improving cerebral blood flow (addressing vascular insufficiency), providing antioxidant neuroprotection, and antagonising platelet-activating factor (PAF) to reduce neuroinflammation.
A 2015 meta-analysis published in the Journal of Alzheimer's Disease, analysing 21 clinical trials, found that Ginkgo (240 mg daily of EGb 761) significantly improved cognitive function, neuropsychiatric symptoms, and daily living activities in patients with dementia. The GuidAge trial (2,854 participants over 5 years) found that consistent Ginkgo use was associated with reduced conversion from MCI to Alzheimer's. In Germany and several other European countries, Ginkgo EGb 761 is a registered medicine for dementia treatment. Standard dosage: 240 mg daily of EGb 761. Caution: Ginkgo has antiplatelet properties - consult your doctor if on anticoagulants.
DHA constitutes approximately 40% of the polyunsaturated fatty acids in the brain and is critical for synaptic membrane structure, signal transduction, and neuroprotection. Post-mortem studies consistently show reduced DHA levels in the brains of Alzheimer's patients. The Framingham Heart Study found that individuals in the top quartile of blood DHA levels had a 47% lower risk of developing dementia over 9 years compared to those in the lowest quartile.
The evidence is strongest for prevention and early-stage intervention. A 2010 RCT published in Alzheimer's & Dementia found that 900 mg DHA daily significantly improved memory and learning in adults with mild cognitive complaints. However, trials in established moderate-to-severe Alzheimer's have shown no benefit - suggesting that omega-3 protects neurons before they are lost but cannot restore neurons already destroyed. This underscores the importance of starting early. Standard dosage: 1,000-2,000 mg combined EPA/DHA daily, with a DHA-dominant formulation preferred for dementia prevention.
Lion's Mane (Hericium erinaceus) stimulates synthesis of Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) via its hericenones and erinacines. NGF is specifically required for the survival of basal forebrain cholinergic neurons - the neurons that die in Alzheimer's disease. Theoretically, maintaining NGF levels could slow the cholinergic degeneration that drives Alzheimer's progression.
A 2009 RCT in Japanese adults aged 50-80 with mild cognitive impairment found that Lion's Mane (3,000 mg daily) significantly improved cognitive scores over 16 weeks. A 2020 study in Nutrients confirmed cognitive benefits in elderly subjects. Preclinical studies have also demonstrated that Lion's Mane reduces amyloid-beta plaque burden and tau hyperphosphorylation in Alzheimer's mouse models, though human studies at this level of pathology are still emerging. Standard dosage: 1,000-3,000 mg daily. No known interactions with dementia medications. See our Mushroom Nootropics guide for more detail.
Citicoline directly addresses the cholinergic deficit central to Alzheimer's by providing choline for acetylcholine synthesis while simultaneously repairing the phospholipid membranes that degenerate in the disease. It is one of the few supplements that has been studied alongside conventional dementia drugs, with evidence suggesting additive benefits.
A 2005 Cochrane-style review analysed 14 trials (involving over 1,000 patients with cognitive impairment) and concluded that citicoline improved memory, attention, and behaviour, with the strongest effects at doses of 1,000-2,000 mg daily. A 2016 meta-analysis in the Journal of the Neurological Sciences confirmed these findings. Citicoline has an excellent safety profile and no significant interactions with cholinesterase inhibitors (donepezil, rivastigmine) - in fact, combining citicoline with these drugs may enhance their effectiveness by providing more substrate for acetylcholine production. Standard dosage: 500-1,000 mg daily. See our Citicoline vs Alpha-GPC comparison.
Huperzine A, derived from the Chinese club moss Huperzia serrata, is a potent, selective, and reversible acetylcholinesterase inhibitor - the same mechanism as the prescription dementia drugs donepezil and rivastigmine. It also has NMDA receptor antagonist properties similar to memantine, and provides antioxidant neuroprotection. This dual mechanism (cholinesterase inhibition + NMDA antagonism) mirrors the two main classes of approved dementia drugs in a single compound.
A 2013 meta-analysis published in PLoS ONE, analysing 20 RCTs involving 1,823 patients, found that Huperzine A significantly improved cognitive function (MMSE scores), daily living activities, and global clinical assessments in Alzheimer's patients. Effects were comparable to donepezil in several head-to-head comparisons. In China, Huperzine A is an approved treatment for Alzheimer's disease. Standard dosage: 200-400 mcg twice daily. Critical warning: Do not combine with prescription cholinesterase inhibitors (donepezil, rivastigmine, galantamine) as the effects are additive and could cause cholinergic excess (nausea, bradycardia, excessive salivation).
Curcumin, the active compound in turmeric, has demonstrated remarkable neuroprotective properties in dementia research. It directly binds to amyloid-beta plaques and inhibits their aggregation, reduces tau phosphorylation, suppresses neuroinflammation via NF-kB pathway inhibition, and chelates redox-active metals (iron and copper) that catalyse oxidative damage in Alzheimer's brains.
Epidemiological data shows that elderly Indian populations, who consume turmeric regularly, have significantly lower rates of Alzheimer's disease. A 2018 UCLA RCT published in the American Journal of Geriatric Psychiatry found that bioavailable curcumin (90 mg Theracurmin twice daily for 18 months) significantly improved memory and attention in non-demented adults, and PET scans showed reduced amyloid and tau accumulation in the brain. Standard dosage: 400-1,000 mg of a bioavailable form (Theracurmin, Longvida, or curcumin with piperine/BioPerine). Standard curcumin has very poor absorption and is largely ineffective.
Phosphatidylserine (PS) supports neuronal membrane integrity, neurotransmitter release, and receptor function - all of which deteriorate in dementia. The FDA permits a qualified health claim linking PS to reduced risk of cognitive dysfunction and dementia. Clinical trials have demonstrated benefits for memory, learning, concentration, and word recall in elderly patients with cognitive impairment.
A pivotal study in Aging Clinical and Experimental Research found that PS (300 mg daily for 6 months) significantly improved cognitive function in patients with early Alzheimer's disease, with the greatest benefits in those with less severe baseline impairment - again highlighting the importance of early intervention. PS also reduces cortisol levels, which is relevant because chronic cortisol elevation accelerates hippocampal atrophy. Standard dosage: 100-300 mg daily, taken with meals. No significant drug interactions.
For individuals concerned about dementia risk due to family history, advancing age, or subjective cognitive complaints. All components have strong safety profiles and can be used indefinitely. This stack targets the major pathological pathways (amyloid, inflammation, neurotrophic support, structural integrity) before significant damage occurs. Most effective when started in the 50s-60s.
For individuals with MCI or early dementia who are not taking prescription cholinesterase inhibitors. Huperzine A provides the same mechanism as prescription drugs, citicoline supplies the raw material for acetylcholine production, and phosphatidylserine supports the membrane environment needed for efficient neurotransmission. Do not use this stack alongside donepezil, rivastigmine, or galantamine.
Designed to be safely combined with prescription dementia medications (donepezil, rivastigmine, galantamine, memantine). Citicoline provides additional choline substrate that may enhance the effectiveness of cholinesterase inhibitors. Lion's Mane, omega-3, and curcumin address pathological mechanisms not targeted by conventional drugs. No Huperzine A is included, as it would duplicate and potentially overload the cholinesterase inhibition already provided by the prescription drug.
The 2020 Lancet Commission on Dementia identified 12 modifiable risk factors that account for approximately 40% of dementia cases worldwide. Addressing these alongside supplementation provides the greatest overall risk reduction:
Dementia prevention and management requires a multi-pronged approach targeting the specific pathological mechanisms involved: amyloid accumulation, cholinergic degeneration, neuroinflammation, oxidative stress, and vascular insufficiency. The most evidence-based supplements are Ginkgo biloba (cerebral blood flow and neuroprotection), omega-3 (structural and anti-inflammatory), Lion's Mane (neurotrophic support), citicoline (cholinergic enhancement), and curcumin (anti-amyloid and anti-inflammatory). Combined with physical exercise, blood pressure management, social engagement, and good sleep, these interventions represent the strongest currently available approach to reducing dementia risk and slowing early-stage progression.
For general age-related cognitive maintenance, see our Nootropics for Seniors guide. For memory-specific strategies, our Memory and Learning guide covers additional compounds. For safe supplement stacking principles, see our Stacking Guide.
No. No supplement can cure or reverse established dementia. Once neurons are lost, they cannot be replaced. However, nootropics can support remaining brain function, reduce the rate of further decline, and improve quality of life. The strongest evidence is for prevention and early intervention - compounds like omega-3, Ginkgo biloba, curcumin, and Lion's Mane can help protect neurons before they are damaged. Starting supplementation early (in the 50s-60s) provides significantly more benefit than waiting until symptoms are advanced.
Yes, Ginkgo biloba has the largest evidence base of any supplement for dementia. A 2015 meta-analysis of 21 trials found that the standardised extract EGb 761 (240 mg daily) significantly improved cognitive function, neuropsychiatric symptoms, and daily living activities in dementia patients. In Germany and several other European countries, Ginkgo EGb 761 is a registered medicine for dementia. It works by improving cerebral blood flow, providing antioxidant neuroprotection, and reducing neuroinflammation. Always use the standardised EGb 761 extract and check with your doctor if you take blood-thinning medications.
Omega-3 (EPA/DHA), citicoline, Lion's Mane, curcumin, phosphatidylserine, and vitamin D are all considered safe alongside donepezil and other cholinesterase inhibitors. Citicoline may actually enhance donepezil's effectiveness by providing additional choline substrate. However, you should avoid Huperzine A, as it is also a cholinesterase inhibitor - combining it with donepezil could cause excessive cholinergic stimulation (nausea, slow heart rate, excessive salivation). Always inform your prescribing doctor about any supplements you are taking.
Promising evidence suggests yes. A 2018 UCLA RCT using PET brain scans found that bioavailable curcumin (180 mg Theracurmin daily for 18 months) led to reduced amyloid and tau accumulation in brain regions involved in memory and emotion, alongside significant improvements in memory and attention. Curcumin directly binds to amyloid-beta and inhibits plaque aggregation. However, standard curcumin supplements have very poor absorption - you must use an enhanced-bioavailability formulation (Theracurmin, Longvida, or curcumin with piperine) to achieve meaningful brain levels.
The earlier the better, ideally starting in your 50s or even earlier if you have a family history. Alzheimer's pathology begins 15-20 years before symptoms appear - amyloid plaques can be detected on brain scans a decade before any cognitive complaints. Neuroprotective compounds like omega-3, curcumin, and Lion's Mane are most effective when started before significant neuronal damage has occurred. Correcting vitamin D deficiency, maintaining omega-3 intake, and regular exercise are low-risk interventions worth starting at any age.